Business Description
Immuron Ltd
ISIN : US45254U1016
Share Class Description:
FRA:ANWA: ADRTotal Employee Number:
7Description
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 56.72 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -4.93 | |||||
Beneish M-Score | -3.19 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 48.1 | |||||
3-Year EBITDA Growth Rate | 6.7 | |||||
3-Year EPS without NRI Growth Rate | 6.7 | |||||
3-Year Book Growth Rate | -26.6 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 27.85 | |||||
9-Day RSI | 38.91 | |||||
14-Day RSI | 43.67 | |||||
3-1 Month Momentum % | -20 | |||||
6-1 Month Momentum % | 54.62 | |||||
12-1 Month Momentum % | -38.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.17 | |||||
Quick Ratio | 5.89 | |||||
Cash Ratio | 5.05 | |||||
Days Inventory | 279.42 | |||||
Days Sales Outstanding | 37.94 | |||||
Days Payable | 170.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.3 | |||||
Shareholder Yield % | -59.56 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 64.5 | |||||
Operating Margin % | -48.3 | |||||
Net Margin % | -49.77 | |||||
EBITDA Margin % | -49.57 | |||||
FCF Margin % | -41.59 | |||||
OCF Margin % | -41.53 | |||||
ROE % | -35.82 | |||||
ROA % | -30.1 | |||||
ROIC % | -92.76 | |||||
3-Year ROIIC % | -1268 | |||||
ROC (Joel Greenblatt) % | -152.68 | |||||
ROCE % | -35.12 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 4.51 | |||||
PS Ratio | 1.42 | |||||
PB Ratio | 1.09 | |||||
Price-to-Tangible-Book | 1.23 | |||||
EV-to-EBIT | -0.8 | |||||
EV-to-EBITDA | -0.8 | |||||
EV-to-Revenue | 0.4 | |||||
EV-to-Forward-Revenue | 1.04 | |||||
EV-to-FCF | -0.95 | |||||
Price-to-GF-Value | 0.46 | |||||
Price-to-Median-PS-Value | 0.1 | |||||
| Price-to-Net-Current-Asset-Value | 1.23 | |||||
| Price-to-Net-Cash | 1.86 | |||||
Earnings Yield (Greenblatt) % | -125.02 | |||||
FCF Yield % | -27.33 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immuron Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 4.527 | ||
| EPS (TTM) (€) | -0.303 | ||
| Beta | 2.3211 | ||
| 3-Year Sharpe Ratio | -0.05 | ||
| 3-Year Sortino Ratio | -0.08 | ||
| Volatility % | 82.51 | ||
| 14-Day RSI | 43.67 | ||
| 14-Day ATR (€) | 0.027602 | ||
| 20-Day SMA (€) | 0.9135 | ||
| 12-1 Month Momentum % | -38.67 | ||
| 52-Week Range (€) | 0.49 - 2.08 | ||
| Shares Outstanding (Mil) | 8.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immuron Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Immuron Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2027-02-25 | In 175 days | ||
| General meeting for 2026 | 2026-11-11 11:15 | In 70 days | ||
| Annual report for 2026 | 2026-09-25 | In 22 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-28 | 0.93 (+0.00%) | ||
| 95th Emerging Growth Conference | 2026-08-19 16:25 | 0.88 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-02-25 | 0.60 (+0.00%) | ||
| General meeting for 2025 | 2025-11-11 11:15 | 1.36 (+0.00%) | ||
| Annual report for 2025 | 2025-09-25 | 1.59 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2025-08-29 | 1.46 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-02-28 | 1.74 (+0.00%) |
Show
Entries
Immuron Ltd Frequently Asked Questions
What is Immuron Ltd(FRA:ANWA)'s stock price today?
The current price of FRA:ANWA is €0.88. The 52 week high of FRA:ANWA is €2.08 and 52 week low is €0.49.
When is next earnings date of Immuron Ltd(FRA:ANWA)?
The next earnings date of Immuron Ltd(FRA:ANWA) is 2027-02-25 Est..
Does Immuron Ltd(FRA:ANWA) pay dividends? If so, how much?
Immuron Ltd(FRA:ANWA) does not pay dividend.
Press Release
Articles on Immuron Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers